Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris
ConditionPsoriasis Vulgaris
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-50
SponsorAswan University
About this trial
Psoriasis is a common immune-mediated inflammatory skin disease affecting at least 100 million individuals worldwide. In Egypt, the prevalence of psoriasis ranges between 0.19% and 3% of the Egyptian people.
It is associated with poor quality of life, reduced life expectancy and multimorbidity including psoriatic arthritis, obesity and cardiovascular disease.
Vaspin (VASP, SERPIN 12) is a recently discovered adipokine that has been isolated from the visceral adipose tissue of a rat model of type 2 diabetes. It is coded by the gene SERPNA12 located on the long arm of chromosome 14q32.13 and consists of six exons and five introns.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Newly diagnosed cases or stopped treatment of at least 6 months of psoriasis patients.
Pateints with any age and gender.
Disqualifiers
Pregnancy and lactation.
Patients with chronic diseases: cardiac diseases, hepatic disorders, chronic renal failure or malignancies.
Patients with associated inflammatory disease such as infections and autoimmune diseases.
Trial population
The study will include (30) psoriasis patients and (30) normal control. and will be conducted on psoriasis patients and the healthy persons whom will be selected from the outpatient clinic of the Dermatology, Venereology, and Andrology Department, at Aswan University Hospital.
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
vaspin gene polymorphism
Biological/Vaccineto detect the correlation between vaspin gene polymorphism and serum vaspin levels among psoriasis patients. * To detect the relationship between the risk of psoriasis and the vaspin gene polymorphism. * To detect correlation between vaspin gene polymorphism and the severity of psoriasis.
Treatment groups
60 Participants
are divided into 2 treatment groupsGroup A: Group A: Psoriasis Patients1 intervention
Group B: Group B: Control Group1 intervention
Trial outcomes
Primary outcomes
1
Detection of vaspin gene polymorphism
Assessment of vaspin gene polymorphism in psoriasis patients to determine the disease severity
Time frame
12 MonthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov